6 news items
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BLRX
17 May 24
unexpected costs or delays in the commercial launch of APHEXDA; risks related to changes in healthcare laws, rules and regulations
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
assessed the cost and healthcare resource utilization impacts of multiple apheresis attempts via a comparison between daily filgrastim (G-CSF) alone
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
BLRX
17 Apr 24
in healthcare laws, rules and regulations in the United States or elsewhere; competitive
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
ABVC
BACK
BLRX
26 Mar 24
: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
BLRX
4 Mar 24
to changes in healthcare laws, rules and regulations in the United States or elsewhere
13du3tevoswxt f146b620
BLRX
28 Feb 24
additional financing, including any unexpected costs or delays in the commercial launch of APHEXDA; risks related to changes in healthcare laws, rules
- Prev
- 1
- Next